AVN now 3% away from being #1 in US -- Stock Picks

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 10:21:12 08/01/01 Wed
Author: AVN now 3% away from being #1 in US
Subject: AVN now 3% away from being #1 in US

AVN now 3% away from being #1 in US

AVANIR Pharmaceuticals price change in past 12 months:
112.9%.
Percentage of all stocks that AVANIR Pharmaceuticals outperformed:
97%

Some of the reasons for the ongoing success of AVN with the wholly owned subsidiary Xenerex are these:

"Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human
antibodies faster and cheaper than its
competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody
Technology plc, Hansen said. "

Bioworld Online,
Aug 21, 2000

also:

AVN's stem cell research relies on adult stem cells and not from embryos. AVN's stem cell reseach is ok by the Pope and
Bush and it is very unique in that they may accomplish what was otherwise thought to be "impossible"!

SAN DIEGO, June 6 /PRNewswire/ -- Xenerex Biosciences, a subsidiary of AVANIR Pharmaceuticals (Amex: AVN -
news), announced today that it has
licensed the rights to a patent for grafting adult human stem cells into severe combined immunodeficient (SCID) mice. The
ability to engraft adult human stem cells,
which may respond to unique antigens with unique antibodies, broadens the company's technological resources with yet
another important option in generating fully
human monoclonal antibodies.

``The addition of this exclusive method extends our technology platform with another methodology for generating fully human
antibodies to a wide array of infectious
diseases and human proteins,'' said J. David Hansen, president and chief operating officer of Xenerex Biosciences. ``With the
addition of this unique approach we
hope to generate B-cells and antibodies, that are difficult or even impossible to obtain by other methods...."

.,.

[ Next Thread | Previous Thread | Next Message | Previous Message ]